Kijimicin sodium

Kijimicin (7 days) sodium inhibits HIV-1 replication in acutely infected H9 cells with an IC₅₀ of 2.2 μg/mL, and shows little cytotoxicity (IC₅₀ = 88 μg/mL)^[1].
Kijimicin (0.1-1000 μg/mL; 72 h) sodium inhibits HIV-1 replication in chronically infected U937 cells^[1].
Kijimicin (0.01, 0.1, 1.0 μg/mL; 7 days) sodium reduces the infectivity of progeny HIV-1 viral particles from H9 cells by more than 1 log^[1].
Kijimicin sodium exhibits antimicrobial activity against Gram-positive bacteria including Staphylococcus aureus FDA 209P (MIC < 0.78 μg/mL), Bacillus cereus ATCC 10702 (MIC < 0.78 μg/mL), and Micrococcus luteus PCI 1001 (MIC < 0.78 μg/mL)^[2].
Kijimicin (7.7 nM; 48 h) sodium inhibits C. parvum growth in HCT-8 cells with an IC₅₀ of 7.7 nM and a CC₅₀ > 20 μM (selectivity index = 2585)^[3].
Kijimicin (1-300 nM; 72 h) sodium inhibits intracellular T. gondii RH-GFP growth in HFF cells with an IC₅₀ of 45.6 nM and a selectivity index of 1019.7^[4].
Kijimicin (1-2000 pM; 1 h) sodium inhibits extracellular T. gondii RH-GFP invasion into Vero cells with an IC₅₀ of 216.6 pM and a selectivity index of 214,681.4^[4].
Kijimicin (50 nM; 24 h) sodium induces morphological changes in T. gondii tachyzoites, including cell swelling and multiple intracellular vacuole-like structures^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.